Trials / Completed
CompletedNCT00723645
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-life Clinical Practice in Spanish Hospitals (FAST-4)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 279 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational, multicenter, nationwide study where information will be collected on the follow-up of participants with chronic hepatitis C virus (HCV) who have a viral response at the end of treatment with pegylated interferon alfa-2b (PEG IFN alfa-2b) plus ribavirin (RBV) administered according to the directions on the products' labeling. No administration of treatment is planned as a result of study enrollment.
Conditions
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2010-04-01
- Completion
- 2011-02-01
- First posted
- 2008-07-29
- Last updated
- 2015-11-30
- Results posted
- 2012-04-23
Source: ClinicalTrials.gov record NCT00723645. Inclusion in this directory is not an endorsement.